CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
+17.6%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$1.89B
AUM Growth
+$1.89B
(+9.7%)
Cap. Flow
-$15.2M
Cap. Flow
% of AUM
-0.81%
Top 10 Holdings %
Top 10 Hldgs %
59.01%
Holding
53
New
4
Increased
8
Reduced
11
Closed
6
Top Buys
| 1 |
BIOA
BioAge Labs, Inc. Common Stock
BIOA
|
$33.9M |
| 2 |
Avidity Biosciences
RNA
|
$28.7M |
| 3 |
MBX
MBX Biosciences, Inc. Common Stock
MBX
|
$18.2M |
| 4 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$15.2M |
| 5 |
AnaptysBio
ANAB
|
$11.5M |
Top Sells
| 1 |
Arcellx
ACLX
|
$23M |
| 2 |
Biohaven
BHVN
|
$20M |
| 3 |
Sarepta Therapeutics
SRPT
|
$19.8M |
| 4 |
Cullinan Oncology
CGEM
|
$19.6M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
$12.8M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CRGX
26
DELISTED
CARGO Therapeutics
CRGX
| $21.8M | 1.16% |
1,182,563
| – | – |
|
27
Arcutis Biotherapeutics
ARQT
$1.91B
| $21.6M | 1.15% |
2,325,000
-200,000
| -8% | -$1.86M |
|
28
Rhythm Pharmaceuticals
RYTM
$6.75B
| $21M | 1.11% |
400,000
-75,000
| -16% | -$3.93M |
|
|
29
Biohaven
BHVN
$1.71B
| $20.1M | 1.07% |
401,963
-400,000
| -50% | -$20M |
|
30
UroGen Pharma
URGN
$896M
| $19.7M | 1.04% |
1,550,000
-100,000
| -6% | -$1.27M |
|
31
Y-mAbs Therapeutics
YMAB
$390M
| $19.1M | 1.01% |
1,450,000
| – | – |
|
|
MBX
32
MBX Biosciences, Inc. Common Stock
MBX
$484M
| $18.2M | 0.96% |
+700,000
| New | +$18.2M |
|
33
Tarsus Pharmaceuticals
TARS
$2.44B
| $16.4M | 0.87% |
500,000
| – | – |
|
34
ArriVent BioPharma
AVBP
$781M
| $13.8M | 0.73% |
585,462
+70,462
| +14% | +$1.66M |
|
|
35
AnaptysBio
ANAB
$630M
| $11.5M | 0.61% |
+342,465
| New | +$11.5M |
|
36
Korro Bio
KRRO
$244M
| $8.88M | 0.47% |
265,826
| – | – |
|
|
SLN
37
Silence Therapeutics
SLN
$237M
| $7.27M | 0.39% |
400,000
-225,000
| -36% | -$4.09M |
|
38
enGene Holdings
ENGN
$249M
| $6.6M | 0.35% |
1,000,000
| – | – |
|
39
Stoke Therapeutics
STOK
$1.08B
| $5.25M | 0.28% |
427,163
| – | – |
|
40
Neurogene
NGNE
$284M
| $4.5M | 0.24% |
107,344
| – | – |
|
41
GH Research
GHRS
$870M
| $3.97M | 0.21% |
593,043
| – | – |
|
42
VYNE Therapeutics
VYNE
$8.09M
| $2.62M | 0.14% |
1,394,336
| – | – |
|
|
VERV
43
DELISTED
Verve Therapeutics
VERV
| $1.69M | 0.09% |
350,000
| – | – |
|
|
ARTV
44
Artiva Biotherapeutics, Inc. Common Stock
ARTV
$77.5M
| $1.6M | 0.08% |
+103,633
| New | +$1.6M |
|
45
RAPT Therapeutics
RAPT
$187M
| $998K | 0.05% |
62,094
| – | – |
|
|
46
Cullinan Oncology
CGEM
$456M
| – | – |
-1,125,000
| Closed | -$19.6M |
|
47
Compass Therapeutics
CMPX
$466M
| – | – |
-2,030,823
| Closed | -$2.03M |
|
48
ImmunityBio
IBRX
$2.24B
| – | – |
0
| – | – |
|
49
IDEAYA Biosciences
IDYA
$2.26B
| – | – |
-245,000
| Closed | -$8.6M |
|
50
Lantheus
LNTH
$3.75B
| – | – |
-75,000
| Closed | -$6.02M |
|